文献速递真菌感染

非HIV感染者隐球菌感染的管理、结局与死亡预测因素:澳大利亚与新西兰46家医院的多中心研究

Management, Outcomes, and Predictors of Mortality of Cryptococcus Infection in Patients Without HIV: A Multicenter Study in 46 Hospitals in Australia and New Zealand.
PubMed 文献 · Clin Infect Dis · 2025-01-01

这项在澳大利亚和新西兰46家医院开展的回顾性研究分析了2015至2019年非HIV隐球菌感染患者的结局。426例患者1年全因死亡率为21%,格特隐球菌感染死亡率低于新型隐球菌(校正OR 0.47),严重神经系统症状是死亡最强预测因素(校正OR 8.46),中枢神经系统感染者中格特隐球菌相关免疫重建炎症反应风险更高(21% vs 3%)。

要点

  • 非HIV隐球菌感染1年全因死亡率为21%,格特隐球菌感染死亡率低于新型隐球菌(校正OR 0.47,95%CI 0.23-0.95)。
  • 严重神经系统症状是死亡最强预测因素(校正OR 8.46,95%CI 2.99-23.98)。
  • 中枢神经系统隐球菌病中格特隐球菌感染相关C-IRIS风险高于新型隐球菌(21% vs 3%,P<.001)。

核心结论

  • 与新型隐球菌相比,格特隐球菌感染死亡率更低,但中枢神经系统感染中C-IRIS风险更高。
  • 严重神经系统症状是死亡的最强预测因素。

研究设计与样本

  • 在澳大利亚和新西兰46家医院开展的回顾性研究,纳入2015至2019年诊断的非HIV隐球菌感染患者,共426例,比较格特隐球菌与新型隐球菌感染结局,多因素分析识别1年内死亡预测因素。

主要发现

  • 426例患者1年全因死亡率为21%。
  • 格特隐球菌感染死亡率低于新型隐球菌(校正OR 0.47,95%CI 0.23-0.95)。
  • 就诊时严重神经系统症状是死亡最强预测因素(校正OR 8.46,95%CI 2.99-23.98)。
  • 中枢神经系统感染者99.5%接受诱导抗真菌治疗,而孤立性肺隐球菌病仅27.7%接受。
  • 中枢神经系统感染中最常见方案为脂质体两性霉素B联合氟胞嘧啶(93.8%,平均疗程31±13天)。

关键数值与推荐

  • 中枢神经系统感染者99.5%接受诱导抗真菌治疗,孤立性肺隐球菌病为27.7%。
  • 中枢神经系统感染最常见方案为脂质体两性霉素B联合氟胞嘧啶(93.8%,平均疗程31±13天)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited data exist regarding outcomes of cryptococcosis in patients without human immunodeficiency virus (HIV), and few studies have compared outcomes of Cryptococcus gattii versus Cryptococcus neoformans infection. METHODS: We conducted a retrospective study in 46 Australian and New Zealand hospitals to determine the outcomes of cryptococcosis in patients without HIV diagnosed between 2015 and 2019 and compared outcomes of C. gattii versus C. neoformans infections. Multivariable analysis identified predictors of mortality within 1 year. RESULTS: Of 426 patients, 1-year all-cause mortality was 21%. Cryptococcus gattii infection was associated with lower mortality than C. neoformans (adjusted odds ratio [OR], 0.47; 95% confidence interval [CI], .23-.95), while severe neurological symptoms at presentation were the strongest predictor of death (adjusted OR, 8.46; 95% CI, 2.99-23.98). Almost all (99.5%) patients with central nervous system (CNS) infection received induction antifungal therapy versus 27.7% with isolated pulmonary cryptococcosis. The most common regimen in CNS disease was liposomal amphotericin B with flucytosine (93.8%; mean duration, 31 ± 13 days). Among patients with CNS cryptococcosis, C. gattii infection was associated with higher risk of immune reconstitution inflammatory response (C-IRIS) than C. neoformans (21% versus 3%, P < .001). Nineteen patients received amphotericin B-based re-induction therapy for suspected relapse, but none had microbiological relapse. Serum cryptococcal antigen positivity and lung imaging abnormalities resolved slowly (resolution at 1 year in 25% and 34% of patients, respectively). CONCLUSIONS: Compared with C. neoformans, C. gattii infection demonstrated lower mortality but higher C-IRIS risk in CNS infection. Severe neurological symptoms were the strongest predictor of mortality.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Coussement J, Heath CH, Roberts MB, et al. Management, Outcomes, and Predictors of Mortality of Cryptococcus Infection in Patients Without HIV: A Multicenter Study in 46 Hospitals in Australia and New Zealand. Clin Infect Dis. 2025. PMID: 39692570. doi:10.1093/cid/ciae630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。